ADA Scientific Sessions 2026 Abstract

Efficacy and Safety of Oral Ribupatide (HRS9531) in Adults with Obesity: A Phase 2 Trial

By Yan Bi, Dan Zhu, Xiaoying Li, Lu Li

Trial in peopleInterventions

The paper

Yan Bi, Dan Zhu, Xiaoying Li, Lu Li

Nanjing

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, late-breaking 2816-LB

doi.org/10.2337/db26-2816-lb

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity